Consistent with this conclusion, loss of cavin-3 expression is more prevalent in late-stage/high-grade cancers than in early-stage/low-grade cancers (Lee et al., 2008; Caren et al., 2011; Wikman et al., 2012). Here, CAVIN3 is linked to cancer.